BioSpace News Archive

Celltrion USA, Inc. (Celltrion USA) today announced its FDA-approved biosimilar, YUFLYMA® (adalimumab-aaty), has been added to CarePartners Specialty Pharmacy Cost Savings Programs.

Mustang Bio, Inc. announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,588,236 of its shares of common stock at a purchase price of $1.70 per share in a registered direct offering priced at-the-market under Nasdaq rules.

PaxMedica, Inc. (Nasdaq: PXMD) a clinical-stage biopharmaceutical company, is excited to announce that the Annals of General Psychiatry, an internationally recognized scientific psychiatry publication, has accepted the manuscript titled “Randomized clinical trial of low dose suramin intravenous infusions for treatment of autism spectrum disorder” for publication.

Aurinia welcomes the 2023 updated recommendations from The European Alliance of Associations for Rheumatology for the management of systemic lupus erythematosus based on emerging new evidence, including a new treatment paradigm for lupus nephritis.

Aytu BioPharma, Inc. announced receipt of U.S. Food & Drug Administration (FDA) approval of the Cotempla XR-ODT® (“Cotempla”) Prior Approval Supplement (PAS).

Medidata today announced a multi-year partnership expansion with Catalyst Clinical Research to support their global oncology brand, Catalyst Oncology.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the development of its next-generation mRNA-launched enveloped virus-like particle (eVLP) technology, which expands on the company’s current proprietary eVLP technology by coding the particles in messenger RNA (mRNA).

Allogene Therapeutics, Inc. today announced that it will report third quarter 2023 financial results on Thursday, November 2, 2023, after the close of the market.

eGenesis will present new data and host a symposium during the IPITA (International Pancreas and Islet Transplant Association), IXA (International Xenotransplantation Association), and CTRMS (Cell Transplant and Regenerative Medicine Society) joint congress, held in San Diego, October 26-29, 2023.

Ascendis Pharma A/S (Nasdaq: ASND) reported updated and new data from its ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 β⁄γ in a poster presentation at ESMO 2023, the annual meeting of the European Society of Medical Oncology held in Madrid, Spain.